Radiopharm Launches ADR Program to Woo U.S. Investors

Radiopharm Theranostics Limited (AU:RAD) has released an update.

Radiopharm Theranostics Limited has announced the launch of its Level 1 American Depositary Receipt (ADR) program, allowing shareholders to trade shares in the U.S. without cross-border complications. The program is seen as a precursor to the company’s plan to list on Nasdaq, aiming to attract U.S. institutional and retail investors with trade initially taking place over-the-counter. The ADR initiative aligns with Radiopharm’s strategic efforts to broaden its investor base in anticipation of its proposed Nasdaq listing.

For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.